• James Bibb received bachelor’s and master’s degrees with honors from Murray State University and the University of Kentucky, respectively. He worked in the Cell Biology and Physiology Department at Washington University in St. Louis before completing his doctorate in cellular and developmental biology at the State University of New York at Stony Brook. His doctoral thesis characterized the poliovirus receptor protein in Eckard Wimmer’s laboratory. Dr. Bibb’s postdoctoral training was conducted in the Laboratory on Molecular and Cellular Neuroscience at the Rockefeller University under the direction of Paul Greengard. His work on the regulation of dopamine neurotransmission was cited in the Nobel Prize in Physiology for Medicine in 2000. From 2001 to 2015 Dr. Bibb was a principal investigator and tenured faculty in the Psychiatry and Neurology and Neurotherapeutics Departments The University of Texas Southwestern Medical Center in Dallas. His lab focuses on signal transduction as it pertains to cognition, neurological and neuropsychiatric disorders, and cancer.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Integrated regulation of PKA by fast and slow neurotransmission in the nucleus accumbens controls plasticity and stress responsesJournal of Biological Chemistry.  298. 2022
    2022 Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters NeurobehaviorFrontiers in Pharmacology.  13. 2022
    2022 RORgt-Expressing Pathogenic CD4+ T Cells Cause Brain Inflammation during Chronic ColitisJournal of Immunology.  208:2054-2066. 2022
    2022 Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancerCell Reports2022
    2021 Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue SurrogatesFrontiers in Endocrinology.  12. 2021
    2021 Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumorsOncogenesis.  10. 2021
    2021 Correction to: Exposure to mild blast forces induces neuropathological effects, neurophysiological deficits and biochemical changes (Molecular Brain, (2018), 11, 1, (64), 10.1186/s13041-018-0408-1)Molecular Brain.  14. 2021
    2021 Neuropathological Effects of Chemotherapeutic DrugsACS Chemical Neuroscience.  12:3038-3048. 2021
    2021 Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapyCancer Gene Therapy.  28:799-812. 2021
    2021 High Fructose Corn Syrup-Moderate Fat Diet Potentiates Anxio-Depressive Behavior and Alters Ventral Striatal Neuronal SignalingFrontiers in Neuroscience.  15. 2021
    2021 Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical PerformanceThe Oncologist.  26:e608-e621. 2021
    2020 Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumorsCancer Gene Therapy.  27:898-909. 2020
    2020 Targeting pheochromocytoma/paraganglioma with polyamine inhibitorsMetabolism: clinical and experimental.  110. 2020
    2020 Phosphoprotein-based biomarkers as predictors for cancer therapyProceedings of the National Academy of Sciences of USA.  117:18401-18411. 2020
    2019 Management of Gastrointestinal Neuroendocrine TumorsClinical Medicine Insights : Endocrinology and Diabetes.  12. 2019
    2018 Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancerOncotarget.  9:37662-37675. 2018
    2018 Exposure to mild blast forces induces neuropathological effects, neurophysiological deficits and biochemical changes 11 Medical and Health Sciences 1109 NeurosciencesMolecular Brain.  11. 2018
    2018 Cdk5 Contributes to Huntington’s Disease Learning and Memory Deficits via Modulation of Brain Region-Specific SubstratesMolecular Neurobiology.  55:6250-6268. 2018
    2018 Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug deliveryTheranostics.  8:1131-1145. 2018
    2016 The Emerging Role of Cdk5 in CancerTrends in Cancer.  2:606-618. 2016
    2016 Cdk5 Modulates Long-Term Synaptic Plasticity and Motor Learning in Dorsolateral StriatumScientific Reports.  6. 2016
    2016 Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injuryJournal of Neurochemistry.  317-327. 2016
    2016 An adenosine-mediated glial-neuronal circuit for homeostatic sleepThe Journal of Neuroscience.  36:3709-3721. 2016
    2016 Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesisOncotarget.  7:6088-6104. 2016
    2015 The role of ventral striatal cAMP signaling in stress-induced behaviorsNature Neuroscience.  18:1094-1100. 2015
    2015 Cdk5 regulates the development of the lymphatic vasculature via phosphorylation of the transcription factor Foxc2Vasomed.  27:195-196. 2015
    2015 Regulation of ERK kinase by MEK1 kinase inhibition in the brainJournal of Biological Chemistry.  290:16319-16329. 2015
    2015 Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2Nature Communications.  6. 2015
    2015 Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesisOncotarget.  6:12080-12093. 2015
    2014 Memory enhancement by targeting Cdk5 regulation of NR2BNeuron.  81:1070-1083. 2014
    2014 P38α regulates SERCA2a functionJournal of Molecular and Cellular Cardiology.  67:86-93. 2014
    2014 Breaking Bad: how does a neuronal protein cause neuroendocrine cancer?Oncotarget.  5:5-6. 2014
    2014 Enhancement of neuromuscular dynamics and strength behavior using extremely low magnitude mechanical signals in miceJournal of Biomechanics.  47:162-167. 2014
    2014 Ischemic stroke injury is mediated by aberrant Cdk5The Journal of Neuroscience.  34:8259-8267. 2014
    2013 The Role of Cdk5 in Neuroendocrine Thyroid CancerCancer Cell.  24:499-511. 2013
    2013 Early Postnatal In Vivo Gliogenesis From Nestin-Lineage Progenitors Requires Cdk5PLoS One.  8. 2013
    2013 P39, the primary activator for cyclin-dependent kinase 5 (CDK5) in oligodendroglia, is essential for oligodendroglia differentiation and myelin repairJournal of Biological Chemistry.  288:18047-18057. 2013
    2013 Cyclin dependent kinase 5 is required for the normal development of oligodendrocytes and myelin formationDevelopmental Biology.  378:94-106. 2013
    2012 A mutation in CLOCK leads to altered dopamine receptor functionJournal of Neurochemistry.  123:124-134. 2012
    2012 Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortexPsychopharmacology.  219:1065-1079. 2012
    2011 Striatal signal transduction and drug addictionFrontiers in Neuroanatomy2011
    2011 Is CREB the angry bird that releases memory in alzheimer'sNeuropsychopharmacology.  36:2153-2154. 2011
    2011 Organophosphates dysregulate dopamine signaling, glutamatergic neurotransmission, and induce neuronal injury markers in striatumJournal of Neurochemistry.  119:303-313. 2011
    2011 The role of Cdk5 in cognition and neuropsychiatric and neurological pathologyBrain Research Bulletin.  85:9-13. 2011
    2011 Sustained hemodynamic stress disrupts normal circadian rhythms in calcineurin-dependent signaling and protein phosphorylation in the heartCirculation Research.  108:437-445. 2011
    2010 Attention-deficit/hyperactivity phenotype in mice lacking the cyclin-dependent kinase 5 cofactor p35Biological Psychiatry.  68:1163-1171. 2010
    2010 Cognition enhancement strategiesThe Journal of Neuroscience.  30:14987-14992. 2010
    2009 Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEPThe Journal of Neuroscience.  29:9330-9343. 2009
    2009 Regulation of hippocampal and behavioral excitability by cyclin-dependent kinase 5PLoS One.  4. 2009
    2008 Cdk5 is essential for adult hippocampal neurogenesisProceedings of the National Academy of Sciences of USA.  105:18567-18571. 2008
    2008 Striatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphologyProceedings of the National Academy of Sciences of USA.  105:18561-18566. 2008
    2008 Negative regulation of cyclin-dependent kinase 5 targets by protein kinase C 2008
    2007 Cdk5 modulates cocaine reward, motivation, and striatal neuron excitabilityThe Journal of Neuroscience.  27:12967-12976. 2007
    2007 Differential regulation of the Cdk5-dependent phosphorylation sites of inhibitor-1 and DARPP-32 by depolarizationJournal of Neurochemistry.  103:1582-1593. 2007
    2007 Alternative roles for Cdk5 in learning and synaptic plasticityBiotechnology Journal.  2:941-948. 2007
    2007 Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradationNature Neuroscience.  10:880-886. 2007
    2007 Regulation of protein phosphatase inhibitor-1 by cyclin-dependent kinase 5Journal of Biological Chemistry.  282:16511-16520. 2007
    2007 Inhibition of Cdk5 in the nucleus accumbens enhances the locomotor-activating and incentive-motivational effects of cocaineProceedings of the National Academy of Sciences of USA.  104:4147-4152. 2007
    2007 Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signalingBrain Research.  1129:1-14. 2007
    2007 Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylationJournal of Biological Chemistry.  282:1687-1694. 2007
    2006 Identification of pyruvate kinase as an antigen associated with Tourette syndromeJournal of Neuroimmunology.  181:165-176. 2006
    2006 Phosphorylation of the tubulin-binding protein, stathmin, by Cdk5 and MAP kinases in the brainJournal of Neurochemistry.  99:237-250. 2006
    2006 Phosphorylation of protein phosphatase inhibitor-1 by protein kinase CJournal of Biological Chemistry.  281:24322-24335. 2006
    2005 Impairment of hippocampal long-term depression and defective spatial learning and memory in p35-/- miceJournal of Neurochemistry.  94:917-925. 2005
    2005 Decoding Dopamine SignalingCell.  122:153-155. 2005
    2005 Control of cyclin-dependent kinase 5 (Cdk5) activity by glutamatergic regulation of p35 stabilityJournal of Neurochemistry.  93:502-512. 2005
    2005 The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performanceThe Journal of Neuroscience.  25:2933-2940. 2005
    2004 Identification of tyrosine hydroxylase as a physiological substrate for Cdk5Journal of Neurochemistry.  91:374-384. 2004
    2004 Molecular characterization of recombinant mouse adenosine kinase and evaluation as a target for protein phosphorylationThe Federation of European Biochemical Societies (FEBS) Journal.  271:3547-3555. 2004
    2004 PKC-α regulates cardiac contractility and propensity toward heart failureNature Medicine.  10:248-254. 2004
    2004 Protein kinases talk to lipid phosphatases at the synapseProceedings of the National Academy of Sciences of USA.  101:1112-1113. 2004
    2004 Role of Cdk5 in drug abuse and plasticityAnnals of the New York Academy of Sciences.  1025:335-344. 2004
    2003 Role of Cdk5 in neuronal signaling, plasticity, and drug abuseNeuroSignals.  12:191-199. 2003
    2003 Cdk5 and the mystery of synaptic vesicle endocytosisThe Journal of Cell Biology.  163:697-699. 2003
    2003 Erratum: Cocaine-induced proliferation of dendritic spines in nucleus accumbens is dependent on the activity of cyclin-dependent kinase-5 (Neuroscience 116: 1 (19-22) PII: S0306452202005602)Neuroscience.  119:619. 2003
    2003 Developmental regulation of the proteolysis of the p35 cyclin-dependent kinase 5 activator by phosphorylationThe Journal of Neuroscience.  23:1189-1197. 2003
    2003 Cocaine-induced proliferation of dendritic spines in nucleus accumbens is dependent on the activity of cyclin-dependent kinase-5Neuroscience.  116:19-22. 2003
    2002 Involvement of DARPP-32 phosphorylation in the stimulant action of caffeineNature.  418:774-778. 2002
    2002 Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: Distinct roles of calcineurin and protein phosphatase-2AJournal of Neurochemistry.  81:832-841. 2002
    2002 Roscovitine: A novel regulator of P/Q-type calcium channels and transmitter release in central neuronsThe Journal of Physiology.  540:761-770. 2002
    2001 Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptorsProceedings of the National Academy of Sciences of USA.  98:11062-11068. 2001
    2001 Phosphorylation of Protein Phosphatase Inhibitor-1 by Cdk5Journal of Biological Chemistry.  276:14490-14497. 2001
    2001 Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5Nature.  410:376-380. 2001
    2001 Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?Journal of Biological Chemistry.  276:251-260. 2001
    2000 Amplification of dopaminergic signaling by a positive feedback loopProceedings of the National Academy of Sciences of USA.  97:12840-12845. 2000
    2000 Drugs of abuse modulate the phosphorylation of ARPP-21, a cyclic AMP-regulated phosphoprotein enriched in the basal gangliaNeuropharmacology.  39:1637-1644. 2000
    2000 Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease miceProceedings of the National Academy of Sciences of USA.  97:6809-6814. 2000
    2000 Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25The Federation of European Biochemical Societies (FEBS) Journal.  267:5983-5994. 2000
    1999 Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neuronsNature.  402:669-671. 1999
    1995 The Human Poliovirus Receptor: Receptor‐Virus Interaction and Parameters of Disease SpecificityAnnals of the New York Academy of Sciences.  753:19-36. 1995
    1994 Interaction of Poliovirus with its Cell Surface Binding SiteVirology.  201:107-115. 1994
    1994 Molecular Characterization of the Cellular Receptor for PoliovirusVirology.  199:105-113. 1994
    1994 Cleavage site of the poliovirus receptor signal sequenceJournal of General Virology.  75:1875-1881. 1994
    1994 The human poliovirus receptor alpha is a serine phosphoproteinJournal of Virology.  68:6111-6115. 1994
    1990 Functional analysis of the modes of anion transport in neutrophils and HL-60 cellsAnnual Review of Physiology.  52:381-397. 1990
    1987 The capsid polypeptides of the 190S virus of Helminthosporium victoriae.Journal of General Virology.  68 ( Pt 7):1791-1800. 1987


    Year Title Altmetric
    2012 Serine and Threonine Phosphorylation.  467-492. 2012
    2011 Serine and Threonine Phosphorylation.  467-492. 2011

    Research Overview

  • Dr. Bibb's research is aimed broadly at understanding the mechanistic basis of cellular functions and disease with emphasis on features of intracellular signal transduction and protein phosphorylation/dephosphorylation. Multidisciplinary approaches and advanced technologies are combined to identify signaling mechanisms and characterize their physiological functions, from basic molecular interactions to behavior or disease. This research has revealed, for example, common features between brain circuitry function, neuronal injury and oncogenesis. His goals are to import clinical information and perspectives into the lab, model and explore disease causes and then return new treatment approaches and solutions to help patients.
  • Education And Training

  • Doctor of Philosophy in Cell / Cellular Biology and Anatomical Sciences, State University of New York System : Stony Brook 1994
  • Full Name

  • James Bibb